157 related articles for article (PubMed ID: 28215618)
1. The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain.
Navarro-Navarro A; Salom D; Martínez-Toldos JJ; Udaondo P; Fernández-Martínez C; Gutiérrez-Arias L; Hervás A; Rodrigo R
Arch Soc Esp Oftalmol; 2017 May; 92(5):245-246. PubMed ID: 28215618
[No Abstract] [Full Text] [Related]
2. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
Cai S; Bressler NM
Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
Jampol LM; Glassman AR; Bressler NM
JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
[TBL] [Abstract][Full Text] [Related]
6. [Budget impact of the incorporation of second-line drug treatment for diabetic macular edema in the Brazilian Unified National Health System from the perspective of the Minas Gerais State Health Department, Brazil].
Izidoro JB; Piazza T; Andrade EIG; Alvares-Teodoro J
Cad Saude Publica; 2019 Aug; 35(8):e00145518. PubMed ID: 31460612
[TBL] [Abstract][Full Text] [Related]
7. An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective.
Meunier A; Opeifa O; Longworth L; Cox O; Bührer C; Durand-Zaleski I; Kelly SP; Gale RP
Eye (Lond); 2024 Jul; 38(10):1917-1925. PubMed ID: 38555401
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept: A Review of Its Use in Diabetic Macular Oedema.
Keating GM
Drugs; 2015 Jul; 75(10):1153-60. PubMed ID: 26056030
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
Holekamp N; Duff SB; Rajput Y; Garmo V
J Med Econ; 2020 Mar; 23(3):287-296. PubMed ID: 31502893
[No Abstract] [Full Text] [Related]
10. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
11. Higher priced drugs are not cost effective for diabetic macular edema, US study finds.
McCarthy M
BMJ; 2016 Jun; 353():i3253. PubMed ID: 27283845
[No Abstract] [Full Text] [Related]
12. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
Krick TW; Bressler NM
Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
[TBL] [Abstract][Full Text] [Related]
13. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
Wood EH; Karth PA; Moshfeghi DM; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
[TBL] [Abstract][Full Text] [Related]
14. Ziv-aflibercept in macular disease.
Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.
Adedokun L; Burke C
Adv Ther; 2016 Jan; 33(1):116-28. PubMed ID: 26747252
[TBL] [Abstract][Full Text] [Related]
16. Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema.
Konidaris VE; Tsaousis KT; Al-Hubeshy Z; Pieri K; Deane J; Empeslidis T
Eye (Lond); 2017 Nov; 31(11):1629-1630. PubMed ID: 28622326
[No Abstract] [Full Text] [Related]
17. Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life.
Schmid MK; Reich O; Faes L; Boehni SC; Bittner M; Howell JP; Thiel MA; Signorell A; Bachmann LM
PLoS One; 2015; 10(8):e0135050. PubMed ID: 26241852
[TBL] [Abstract][Full Text] [Related]
18. Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Glassman AR; Liu D; Jampol LM; Sun JK;
Invest Ophthalmol Vis Sci; 2018 Mar; 59(3):1199-1205. PubMed ID: 29625440
[TBL] [Abstract][Full Text] [Related]
19. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF Molecules for the Management of Diabetic Macular Edema.
Bandello F; Cicinelli MV; Parodi MB
Curr Pharm Des; 2015; 21(32):4731-7. PubMed ID: 26350530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
